New chemo cocktail shows promise for tough-to-treat colorectal cancer
NCT ID NCT04230187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a more intense chemotherapy regimen (mFOLFOXIRI) plus the drug bevacizumab against a standard regimen (mFOLFOX-6) plus bevacizumab as a first treatment for people with advanced colorectal cancer that cannot be removed by surgery. The trial includes 528 participants in China and measures how long the cancer stays under control, tumor shrinkage, and side effects. The goal is to find a more effective option for Asian patients who often have trouble tolerating standard high-dose treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gastrointestinal Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510655, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?